肿瘤性染色体组：肿瘤疾病中基于性别的差异概况。

OncoSexome: the landscape of sex-based differences in oncologic diseases.

作者信息

Shen Xinyi, Zhang Yintao, Li Jiamin, Zhou Ying, Butensky Samuel D, Zhang Yechi, Cai Zongwei, DeWan Andrew T, Khan Sajid A, Yan Hong, Johnson Caroline H, Zhu Feng

机构信息

College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, State Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou 310058, China.

Department of Environmental Health Sciences, Yale School of Public Health, Yale University, New Haven 06510, USA.

出版信息

Nucleic Acids Res. 2025 Jan 6;53(D1):D1443-D1459. doi: 10.1093/nar/gkae1003.

DOI:10.1093/nar/gkae1003

PMID:39535034

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11701605/

Abstract

The NIH policy on sex as biological variable (SABV) emphasized the importance of sex-based differences in precision oncology. Over 50% of clinically actionable oncology genes are sex-biased, indicating differences in drug efficacy. Research has identified sex differences in non-reproductive cancers, highlighting the need for comprehensive sex-based cancer data. We therefore developed OncoSexome, a multidimensional knowledge base describing sex-based differences in cancer (https://idrblab.org/OncoSexome/) across four key topics: antineoplastic drugs and responses (SDR), oncology-related biomarkers (SBM), risk factors (SRF) and microbial landscape (SML). SDR covers sex-based differences in 2051 anticancer drugs; SBM describes 12 551 sex-differential biomarkers; SRF illustrates 350 sex-dependent risk factors; SML demonstrates 1386 microbes with sex-differential abundances associated with cancer development. OncoSexome is unique in illuminating multifaceted influences of biological sex on cancer, providing both external and endogenous contributors to cancer development and describing sex-based differences for the broadest oncological classes. Given the increasing global research interest in sex-based differences, OncoSexome is expected to impact future precision oncology practices significantly.

摘要

美国国立卫生研究院（NIH）关于将性别作为生物学变量（SABV）的政策强调了性别差异在精准肿瘤学中的重要性。超过50%的具有临床可操作性的肿瘤基因存在性别偏向，这表明药物疗效存在差异。研究已经确定了非生殖系统癌症中的性别差异，凸显了全面的基于性别的癌症数据的必要性。因此，我们开发了OncoSexome，这是一个多维知识库，描述了癌症中基于性别的差异（https://idrblab.org/OncoSexome/），涵盖四个关键主题：抗肿瘤药物与反应（SDR）、肿瘤相关生物标志物（SBM）、风险因素（SRF）和微生物景观（SML）。SDR涵盖了2051种抗癌药物的性别差异；SBM描述了12551种性别差异生物标志物；SRF说明了350种性别依赖性风险因素；SML展示了1386种与癌症发展相关的具有性别差异丰度的微生物。OncoSexome在阐明生物性别对癌症的多方面影响方面独具特色，提供了癌症发展的外部和内源性因素，并描述了最广泛肿瘤类别中的性别差异。鉴于全球对性别差异的研究兴趣日益增加，OncoSexome有望对未来的精准肿瘤学实践产生重大影响。